Skip to main navigation PATIENT PHARMA DIAGNOSTICS COVID-19 SCIENCE CLINICAL STUDIES Press Releases Home Investors Press Releases Press Releases YEAR 2021 November 18, 2021 CENTOGENE to Announce Third Quarter 2021 Financial Results on November 24, 2021 CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced that it will issue its financial results for Read More November 4, 2021 CENTOGENE Expands Partnership With Agios to Generate Novel Insights Into Rare Blood Diseases Providing Global Clinical Trial Support for Thalassemia and Sickle Cell Disease Will Deepen Understanding of Disease Characterization in the Search for a Treatment CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. Read More October 28, 2021 CENTOGENE Enrolls First Patient in Frontotemporal Dementia (FTD) Clinical Study FTD is a rapidly progressing neurodegenerative disease; up to 30% of all cases worldwide caused by genetic mutations, including the progranulin gene mutation (FTD-GRN) Study will enroll and genetically test over 3,000 FTD patients at multiple sites in seven countries There are currently no Read More October 6, 2021 CENTOGENE and Twist Bioscience to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases Combining Expertise to Advance Precision Medicine, While Enabling a More Efficient and Timely Diagnosis of Rare Diseases Around the World CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. Read More September 29, 2021 CENTOGENE’s Ground-Breaking Family Genetic Research Published in the New England Journal of Medicine Reveals Path to Potential Cure for Structural Birth Defects Collaborative research utilized insights gained from CENTOGENE’s rare disease-centric Bio/Databank to help analyze data of more than 20,000 families Enabled testing of successful targeted therapeutic approach that restored embryonic development in preclinical models of birth defects Results reflect Read More September 7, 2021 CENTOGENE Reports Second Quarter 2021 Financial Results Strong Revenues and Steady Return to Core Business Growth; Surpasses Milestone of 200 Scientific Publications, Highlighting Value of Bio/Databank CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on Read More September 1, 2021 CENTOGENE to Announce Second Quarter 2021 Financial Results on September 7, 2021 CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced that it will issue its financial results for Read More July 27, 2021 CENTOGENE Appoints Patrice P. Denèfle as Chief Scientific Officer to Lead Its Data-Driven Approach to Reinvent Rare Disease Drug Discovery and Development CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 27, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the appointment of Dr. Patrice P. Read More June 25, 2021 CENTOGENE Announces Shareholders Approve All Resolutions at Annual General Meeting CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 25, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the voting results of the Company’s Annual Read More June 22, 2021 CENTOGENE Sets Mission to Enable the Cure of 100 Rare Diseases Within the Next 10 Years Highlights strategic priorities to lead data-driven insights creation for rare diseases at its Virtual Investor Event Company outlines significant value creation potential to contribute to the diagnosis of rare diseases and to enable the development of novel therapeutics Focuses on leveraging its Read More June 16, 2021 CENTOGENE Reports First Quarter 2021 Financial Results in the Lead Up to Virtual Investor Event Further signs of recovery in the core rare disease business Recorded revenues of €65.0 million in Q1 2021, driven by revenues from COVID-19 testing, up over 400% compared to €12.1 million in Q1 2020 Achieved positive adjusted EBITDA, driven by COVID-19 testing revenues, while continuing to invest Read More June 9, 2021 CENTOGENE to Announce Q1 2021 Financial Results on June 16, 2021 CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 09, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced that it will issue its financial results for the Read More June 7, 2021 CENTOGENE Announces Virtual Investor Event New leadership team to present vision, strategy, and execution roadmap CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 07, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare Read More June 2, 2021 CENTOGENE Initiates EFRONT Study to Identify Patients With Genetic Forms of Frontotemporal Dementia Observational Study to Advance Genetic Understanding of FTD Being Conducted With Support From Alector CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 02, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, Read More June 1, 2021 CENTOGENE Launches NEW CentoXome® - An Enhanced Whole Exome Sequencing Solution World leader and trusted partner in rare diseases releases enhanced Whole Exome Sequencing (WES) solution to improve diagnosis in complex and unsolved patient cases NEW CentoXome® provides best-in-class clinical insights based on CENTOGENE’s unique rare disease-centric Bio/Databank, enabling more Read More May 26, 2021 CENTOGENE Announces the Nomination of Rene Just as Chief Financial Officer CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 26, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the nomination of Rene Just as Chief Financial Read More May 18, 2021 CENTOGENE Appoints Michael Motz as Chief Commercial Officer, Pharmaceuticals CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 18, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical Read More May 10, 2021 CENTOGENE Extends Global Parkinson’s Disease Study Providing patients with genetic testing designed to accelerate the diagnosis and personalized treatment of Parkinson’s disease (PD) The Rostock International Parkinson's Disease (ROPAD) Study aims to characterize the genetics of PD to establish a better understanding of disease progression, Read More May 6, 2021 New CentoMD® 6.0 Update Brings Deeper Insights Into Rare Diseases CENTOGENE’s rare disease mutation database offers new features and previously unpublished variants Database has grown to more than 465,000 analyzed patients, with more than 225,000 being linked to HPO terms Release includes increase of almost 19 million to over 31 million unique variants New Read More May 5, 2021 CENTOGENE Discovers Six New Rare Diseases by Leveraging the Strength of Its Bio/Databank Research leads to diagnosis and treatment options for rare disease patients More than half of patients with genetic diseases remain undiagnosed, even after performing Exome and Genome Sequencing By performing deep genetic analyses and Bio/Databank mining, CENTOGENE discovers six novel gene-disease Read More April 15, 2021 CENTOGENE Reports Record Fourth Quarter and Full Year 2020 Financial Results Delivers very strong financial results in unprecedented year Revenues more than doubled in FY 2020 compared to FY 2019 to a record €128.4 million, with Q4 2020 revenues nearly quadrupling year-over-year to a record €70.3 million Achieved highest annual adjusted EBITDA in CENTOGENE’s history, driven Read More April 14, 2021 CENTOGENE Extends Partnership With Takeda CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, April 14, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical Read More April 8, 2021 CENTOGENE to Announce Full Year 2020 Financial Results on April 15, 2021 CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, April 08, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical Read More March 9, 2021 CENTOGENE Reaches 10,000 Participant Milestone in Global Parkinson’s Disease Study Rostock International Parkinson's Disease (ROPAD) Study aims to characterize the genetics of PD to establish a better understanding of the disease progression, diagnosis, and treatment Significant milestone of 10,000 participants reached With over 120 study sites around the world, CENTOGENE is Read More Toolkit Print Page Email Alerts Contact IR Pharma Diagnostics Company Newsletter SUBSCRIBE NOW Follow Us © 2021 CENTOGENE N.V. Imprint Data Protection HIPAA Privacy Terms of Use Terms and Conditions Whistleblower Hotline